FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007473361> ?p ?o ?g. }

• W2007473361 endingPage "498" @default.
• W2007473361 startingPage "488" @default.
• W2007473361 abstract "Radical radiotherapy is a standard form of management of localised prostate cancer. Conformal treatment planning spares adjacent normal tissues reducing treatment-related side effects and may permit safe dose escalation. We have tested the effects on tumour control and side effects of escalating radiotherapy dose and investigated the appropriate target volume margin. After an initial 3–6 month period of androgen suppression, 126 men were randomised and treated with radiotherapy using a 2 by 2 factorial trial design. The initial radiotherapy tumour target volume included the prostate and base of seminal vesicles (SV) or complete SV depending on SV involvement risk. Treatments were randomised to deliver a dose of 64 Gy with either a 1.0 or 1.5 cm margin around the tumour volume (1.0 and 1.5 cm margin groups) and also to treat either with or without a 10 Gy boost to the prostate alone with no additional margin (64 and 74 Gy groups). Tumour control was monitored by prostate-specific antigen (PSA) testing and clinical examination with additional tests as appropriate. Acute and late side effects of treatment were measured using the Radiation Treatment and Oncology Groups (RTOG) and LENT SOM systems. The results showed that freedom from PSA failure was higher in the 74 Gy group compared to the 64 Gy group, but this did not reach conventional levels of statistical significance with 5-year actuarial control rates of 71% (95% CI 58–81%) in the 74 Gy group vs 59% (95% CI 45–70%) in the 64 Gy group. There were 23 failures in the 74Gy group and 33 in the 64 Gy group (Hazard ratio 0.64, 95% CI 0.38–1.10, P=0.10). No difference in disease control was seen between the 1.0 and 1.5 cm margin groups (5-year actuarial control rates 67%, 95% CI 53–77% vs 63%, 95% CI 50–74%) with 28 events in each group (Hazard ratio 0.97, 95% CI 0.50–1.86, P=0.94). Acute side effects were generally mild and 18 weeks after treatment, only four and five of the 126 men had persistent ⩾Grade 1 bowel or bladder side effects, respectively. Statistically significant increases in acute bladder side effects were seen after treatment in the men receiving 74 Gy (P=0.006), and increases in both acute bowel side effects during treatment (P=0.05) and acute bladder sequelae (P=0.002) were recorded for men in the 1.5 cm margin group. While statistically significant, these differences were of short duration and of doubtful clinical importance. Late bowel side effects (RTOG⩾2) were seen more commonly in the 74 Gy and 1.5 cm margin groups (P=0.02 and P=0.05, respectively) in the first 2 years after randomisation. Similar results were found using the LENT SOM assessments. No significant differences in late bladder side effects were seen between the randomised groups using the RTOG scoring system. Using the LENT SOM instrument, a higher proportion of men treated in the 74 Gy group had Grade ⩾3 urinary frequency at 6 and 12 months. Compared to baseline scores, bladder symptoms improved after 6 months or more follow-up in all groups. Sexual function deteriorated after treatment with the number of men reporting some sexual dysfunction (Grade⩾1) increasing from 38% at baseline to 66% at 6 months and 1 year and 81% by year 5. However, no consistent differences were seen between the randomised groups. In conclusion, dose escalation from 64 to 74 Gy using conformal radiotherapy may improve long-term PSA control, but a treatment margin of 1.5 cm is unnecessary and is associated with increased acute bowel and bladder reactions and more late rectal side effects. Data from this randomised pilot study informed the Data Monitoring Committee of the Medical Research Council RT 01 Trial and the two studies will be combined in subsequent meta-analysis." @default.
• W2007473361 created "2016-06-24" @default.
• W2007473361 creator A5011222815 @default.
• W2007473361 creator A5011770259 @default.
• W2007473361 creator A5012480876 @default.
• W2007473361 creator A5015984938 @default.
• W2007473361 creator A5022068541 @default.
• W2007473361 creator A5025921361 @default.
• W2007473361 creator A5047234703 @default.
• W2007473361 creator A5059792318 @default.
• W2007473361 creator A5062132667 @default.
• W2007473361 creator A5063051257 @default.
• W2007473361 date "2005-02-01" @default.
• W2007473361 modified "2023-10-18" @default.
• W2007473361 title "Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects" @default.
• W2007473361 cites W139914037 @default.
• W2007473361 cites W1868380765 @default.
• W2007473361 cites W1868732334 @default.
• W2007473361 cites W190857994 @default.
• W2007473361 cites W1965893444 @default.
• W2007473361 cites W1968757243 @default.
• W2007473361 cites W1979807657 @default.
• W2007473361 cites W1979877297 @default.
• W2007473361 cites W1979914233 @default.
• W2007473361 cites W1984651023 @default.
• W2007473361 cites W1989135507 @default.
• W2007473361 cites W1989650089 @default.
• W2007473361 cites W2001664478 @default.
• W2007473361 cites W2010796934 @default.
• W2007473361 cites W2014146956 @default.
• W2007473361 cites W2017298571 @default.
• W2007473361 cites W2019378587 @default.
• W2007473361 cites W2025027678 @default.
• W2007473361 cites W2025895255 @default.
• W2007473361 cites W2036158173 @default.
• W2007473361 cites W2036533864 @default.
• W2007473361 cites W2036571755 @default.
• W2007473361 cites W2040091965 @default.
• W2007473361 cites W2043945205 @default.
• W2007473361 cites W2049153532 @default.
• W2007473361 cites W2060708205 @default.
• W2007473361 cites W2061444197 @default.
• W2007473361 cites W2063960686 @default.
• W2007473361 cites W2074421032 @default.
• W2007473361 cites W2074956054 @default.
• W2007473361 cites W2083977059 @default.
• W2007473361 cites W2084269392 @default.
• W2007473361 cites W2085907209 @default.
• W2007473361 cites W2087797207 @default.
• W2007473361 cites W2089403922 @default.
• W2007473361 cites W2091013692 @default.
• W2007473361 cites W2091094692 @default.
• W2007473361 cites W2093183364 @default.
• W2007473361 cites W2093485750 @default.
• W2007473361 cites W2094023555 @default.
• W2007473361 cites W2099288242 @default.
• W2007473361 cites W2103429819 @default.
• W2007473361 cites W2114490291 @default.
• W2007473361 cites W2121704058 @default.
• W2007473361 cites W2130935668 @default.
• W2007473361 cites W2144498681 @default.
• W2007473361 cites W2146317083 @default.
• W2007473361 cites W2146421906 @default.
• W2007473361 cites W2146780512 @default.
• W2007473361 cites W2150373135 @default.
• W2007473361 cites W2150780724 @default.
• W2007473361 cites W2154268701 @default.
• W2007473361 cites W2163120057 @default.
• W2007473361 cites W2163217542 @default.
• W2007473361 cites W2274851081 @default.
• W2007473361 cites W2468411646 @default.
• W2007473361 cites W2731200312 @default.
• W2007473361 cites W4230657972 @default.
• W2007473361 cites W4243651860 @default.
• W2007473361 cites W4253473049 @default.
• W2007473361 cites W4298841367 @default.
• W2007473361 cites W4300555223 @default.
• W2007473361 cites W9085563 @default.
• W2007473361 doi "https://doi.org/10.1038/sj.bjc.6602301" @default.
• W2007473361 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2362084" @default.
• W2007473361 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15685244" @default.
• W2007473361 hasPublicationYear "2005" @default.
• W2007473361 type Work @default.
• W2007473361 sameAs 2007473361 @default.
• W2007473361 citedByCount "201" @default.
• W2007473361 countsByYear W20074733612012 @default.
• W2007473361 countsByYear W20074733612013 @default.
• W2007473361 countsByYear W20074733612014 @default.
• W2007473361 countsByYear W20074733612015 @default.
• W2007473361 countsByYear W20074733612016 @default.
• W2007473361 countsByYear W20074733612017 @default.
• W2007473361 countsByYear W20074733612018 @default.
• W2007473361 countsByYear W20074733612019 @default.
• W2007473361 countsByYear W20074733612020 @default.
• W2007473361 countsByYear W20074733612021 @default.
• W2007473361 countsByYear W20074733612022 @default.
• W2007473361 countsByYear W20074733612023 @default.
• W2007473361 crossrefType "journal-article" @default.

• next